VRDN - Viridian Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Boulder,
United States
Type: Equity
VRDN price evolution
VRDN
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.01 | $0.1 | $0.1 | |
| Inventory | ||||
| Total current assets | $767.36 | $581.66 | $626.82 | $486.48 |
| Long term investments | ||||
| Property, plant & equipment | $3.69 | $3.34 | $3.01 | $3.34 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $771.9 | $585.66 | $630.38 | $490.42 |
| Current liabilities | ||||
| Accounts payable | $6.34 | $3.14 | $2.68 | $2.24 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $41.36 | $36.76 | $26.13 | $26.64 |
| Long term debt | $20.52 | $17.49 | $20.33 | $20.2 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $64.4 | $56.33 | $47.85 | $48.4 |
| Shareholders' equity | ||||
| Retained earnings | -$916.13 | -$839.44 | -$774.45 | -$725.91 |
| Other shareholder equity | $0.93 | -$0.54 | -$0.37 | $0.34 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $45.9 | |||
| Short term investments | ||||
| Net receivables | $0.1 | $0.1 | $0.45 | |
| Inventory | ||||
| Total current assets | $486.48 | $431.17 | $200.16 | $129.61 |
| Long term investments | ||||
| Property, plant & equipment | $3.34 | $2.94 | $2.06 | $0.31 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1.64 | |||
| Total investments | ||||
| Total assets | $490.42 | $435.09 | $203.71 | $131.25 |
| Current liabilities | ||||
| Accounts payable | $2.24 | $14.23 | $2.33 | $0.67 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $26.64 | $33.35 | $13.64 | $10.67 |
| Long term debt | $20.2 | $4.64 | ||
| Total noncurrent liabilities | $0.54 | |||
| Total debt | ||||
| Total liabilities | $48.4 | $40.03 | $15.99 | $11.22 |
| Shareholders' equity | ||||
| Retained earnings | -$725.91 | -$488.17 | -$358.3 | -$278.89 |
| Other shareholder equity | $0.34 | -$0.39 | -$0.16 | $180.79 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.09 | $0.07 | $0.07 | $0.07 |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $83.57 | $72.26 | $55.97 | $71.55 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $6.79 | $7.19 | $7.36 | $4.62 |
| Net income | ||||
| Net income | -$76.69 | -$64.99 | -$48.54 | -$66.86 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.31 | $1.77 | $1.05 | |
| Cost of revenue | ||||
| Gross Profit | $1.05 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $254.76 | $136.08 | $111.43 | |
| Operating income | -$110.38 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $16.72 | $4.43 | $0.51 | |
| Net income | ||||
| Net income | -$237.73 | -$129.87 | -$110.72 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$165.74 | -$81.07 | -$143.04 | -$94.25 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $422.21 | $177.19 | $177.08 | $225.67 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $97.49 | $4.84 | -$11.19 | -$52.75 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | -$110.72 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$29.78 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$94.25 | -$115.13 | -$74.29 | -$50.48 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $225.67 | $322.24 | $125.28 | $101.31 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$52.75 | $113.27 | -$3.59 | $21.05 |
News
Fundamentals
| Market cap | $1.29B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 79.18M |
| Revenue | $302.00K |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$257.08M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -5.01 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 4.27K |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$3.25 |
|---|---|
| ROA | -41.49% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 18.55 |
| Quick ratio | N/A |